Loading company…
Busan-based PharmCADD provides drug discovery services, including its PharmVAC platform for mRNA vaccine development.
Founded in 2019 and headquartered in Busan, South Korea, PharmCADD applies quantum mechanics, molecular dynamics and artificial intelligence to drug discovery. Its PharmVAC platform targets mRNA vaccine development, and its work includes key kinases such as MEK1/2. Revenue comes mainly from partnerships with pharmaceutical companies, including milestone payments, licensing fees and revenue sharing. In April 2021 it raised USD 16.000 mn in a Series B round from DSC Investment, KB Securities, KDB Capital, SD Group and Woori Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in